Drug
Qls4131
Qls4131: highest development phase Phase 3, developed by Qilu Pharmaceutical Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Qilu Pharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| QLS4131 NCT07933432 | Phase 3 | Relapsed or Refractory Multiple Myeloma |
Latest
No recent events.
Follow Qls4131 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.